Company Overview and News
KUALA LUMPUR: Cahya Mata Sarawak Bhd (CMSB) has appointed Tan Sri Abdul Rashid Abdul Manaf as its independent and non-executive group chairman effective Oct 1.
2852 8206 8664
KUALA LUMPUR (Sept 26): Cahya Mata Sarawak Bhd (CMSB) has appointed Tan Sri Abdul Rashid Abdul Manaf as its independent and non-executive group chairman effective Oct 1.
2852 8206 8664
Eco World Development Group Bhd (Sept 21, RM1.23) Maintain add with an unchanged target price (TP) of RM1.42: Eco World Development Group Bhd’s (EcoWorld) core net profit for the cumulative nine months of the financial year ending Oct 31, 2018 (9MFY18) (excluding a RM94.8 million gain on disposal of a 40% stake in Eco Grandeur in 9MFY17) made up 53% of our and 56% of Bloomberg consensus full-year estimates.
KUALA LUMPUR (Sept 20): Eco World Development Group Bhd (EcoWorld) saw its net profit jump 47.6% to RM38.52 million in the third financial quarter ended July 31, 2018 (3QFY18) from RM26.09 million a year ago, on higher profit contribution from projects undertaken by its joint ventures (JVs).
8206 BSMAF 1818
KUALA LUMPUR: Eco World Development Group Bhd said its home ownership campaign launched in June boosted the group’s sales and profit in the third quarter ended July 31.
PENANG: Eco World Development Group Bhd (EcoWorld) will be launching the first phase of its Brydon collection of semi-detached houses and bungalows in its Eco Horizon township development at Batu Kawan, Penang in the fourth quarter of the year (4Q18).
Kohn and Prashant (front row, sixth and seventh from left) and representatives of winning employers after the award presentation ceremony in Kuala Lumpur. Photo by Sam Fong
8206 8664 MYPRY 5168 5014 HRGHY
It’s a deal: Liew (standing, left) and Invesco Real Estate director John German (standing, right) look on as EcoWorld London CEO Cheong Heng Leong (seated, left) and Invesco Real Estate managing director Simon Redman sign the Heads of Terms.
PETALING JAYA: Property consultants are petrified by Prime Minister Tun Dr Mahathir Mohamad’s statement that foreigners will not be allowed to buy residential units in Forest City, one of four islands being reclaimed by Chinese developer Country Garden Holdings Co in a multi-billion venture.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...